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The antiangiogenic factor METH-2 (ADAMTS-8) was identified in a previous dual-channel cDNA microarray analysis to be at least
two-fold under-represented in 85% (28 out of 33) of primary non-small-cell lung carcinomas (NSCLCs). This observation has been
validated in an independent series of NSCLCs and adjacent normal tissues by comparative multiplex RT—PCR, and METH-2 mRNA
expression was dramatically reduced in all 23 tumour samples analysed. Immunohistochemical analysis of the same sample set
demonstrated that METH-2 was strongly expressed in 14 out of 19 normal epithelial sites examined but only one out of 20 NSCLCs.
DNA methylation analysis of the proximal promoter region of this gene revealed abnormal hypermethylation in 67% of the
adenocarcinomas and 50% of squamous cell carcinomas, indicating that epigenetic mechanisms are involved in silencing this gene in
NSCLC. No homozygous deletions of METH-2 were found in lung cancer cell lines. Allelic imbalance in METH-2 was assessed by an
intronic single nucleotide polymorphism (SNP) assay and observed in 44% of informative primary samples. In conclusion, the
downregulation of METH-2 expression in primary NSCLC, often associated with promoter hypermethylation, is a frequent event,
which may be related to the development of the disease.
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The ability of a tumour to grow more than 2–3mm
3 relies on the
creation of a new blood supply, which facilitates growth by
allowing the delivery of nutrients and oxygen to the new tissue
(Folkman and Cotran, 1976; Folkman et al, 1989). This process,
angiogenesis, is the formation of new blood vessels from the
existing vasculature, more specifically from the vascular endothe-
lial cells. Tumour angiogenesis involves a number of factors that
may be paracrine from the adjacent tumour, stromal cells,
inflammatory cells, extracellular matrix (ECM), and/or autocrine
from the endothelial cells themselves. Antiangiogenesis ap-
proaches are considered to be possible adjuncts to conventional
therapy in the treatment of lung cancer patients.
METH-2 (ADAMTS-8) is a member of the ADAMTS family (a
disintegrin and metalloprotease with thrombospondin-1-like
motifs). This family of genes shows significant sequence similarity
to snake venom metalloprotease and disintegrin. METH-2 was
fully characterised by Vazquez et al (1999) along with its
counterpart METH-1 (ADAMTS1). METH-2 is expressed in
various human tissues, exhibiting high levels in the adult and
fetal normal lung. It is a single-copy gene, and encodes a
proteolytically processed protein. METH-2 protein has a more
powerful antiangiogenic effect than thrombospondin-1 or endo-
statin, and can specifically suppress endothelial cell proliferation
(Vazquez et al, 1999). Human METH-2 is located at 11q25
(Georgiadis et al, 1999).
The role of METH genes in cancer development is largely
unclear. Masui et al (2001) have reported that METH-1 appears to
be involved in the progression of pancreatic cancer while METH-2
was not expressed. To date, to our knowledge, there is no specific
report on the involvement of these genes in lung cancer. However,
METH-2 was highlighted in our previous study (Heighway et al,
2002) in which a panel of cDNA microarrays comprising 47650
transcript elements was used to analyse gene expression patterns
in 39 ressected primary human non-small-cell lung tumours that
were compared to paired normal lung tissues. These data
demonstrated that METH-2 was significantly under-represented
(two-fold or lower) in 85% (28 out of 33) of the analysed non-
small-cell tumours. This suggested the possibility that the loss of
METH-2 function might be an important factor in tumour
angiogenesis. In this study, we have validated our previous
microarray observations of METH-2 expression in an independent
series of non-small-cell lung carcinomas (NSCLCs) and we have
investigated possible genetic and epigenetic mechanisms respon-
sible for this inactivation.
MATERIALS AND METHODS
Tissues and cell lines
In all, 12 adenocarcinomas (ADCs) and 11 squamous cell
carcinomas (SCCs) were selected from our tumour bank, along
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swith their paired normal tissues. All these tumours had a T
stage¼2 while the N stage varied (Table 1). The mean age of the
patients was 64. All 23 tissue pairs were used for examining the
expression of METH-2. DNA from 27 additional NSCLC samples
(15 SCC, 12 ADC) was used in the methylation analysis. Micro-
scopic examination of H&E-stained sections was carried out to
confirm that tumour tissue sections contained 470% tumour cells.
The following nine lung cancer cell lines obtained from
American Type Culture Collection (Rockville, MD, USA) were
used in the homozygous deletion screening: squamous: CRL5802,
HTB182, SKMES, SKMES1, LUDLU1; adenocarcinoma: A549,
SKLU1; small cell: DMS53; large cell: CORL23.
DNA extraction, RNA extraction and cDNA synthesis
Genomic DNA from cell lines and the set of 27 unpaired tumours
was extracted as previously described (Liloglou et al, 2000;
Heighway et al, 2003). Total RNA and genomic DNA from the 23
normal–tumour paired samples was extracted from 20 40mm
frozen tissue sections using the Qiagen
s RNA/DNA extraction kit,
following the manufacturer’s protocol. RNA was aliquotted into 1–
2mg amounts for subsequent cDNA synthesis in 20ml reactions
using the Promega Reverse Transcription System, using oligo-dT
primers. RNA aliquots were stored at –80
oC; cDNAs and genomic
DNAs were stored at  201C.
Comparative multiplex RT–PCR
To compare the relative expression levels of METH-2 in multiple
paired normal and tumour lung cancer tissues, multiplex RT–PCR
reactions were set up as described. Two primer sets were used in
the same PCR reaction: METH-2 primers spanning exons 3 and 4
(forward: 50-AAC AAA AGC TGC TCC GTG AT-30; reverse: 50-TCT
GGT TCA GGT GGA CGA AC-30) and a control gene primer set
(control gene – O28, KIAA0228: amyloid beta precursor protein-
binding protein, acc. no. D86981) that had previously been found
to be expressed at a constant level in normal and lung cancer
tissues (Heighway et al, 2002; forward: 50-GAA CTG TGT GCA CTC
CTA TTT G-30; reverse: 50-CCG TGC CAA ATA CAC TGC ATG GT-
30). PCR reactions (50ml) were set up, which contained 1mlo f
cDNA, 5mlo f1 0   buffer, 0.5U of Roche Taq polymerase, 1ml
dNTPs (5mM), 1ml of O28 primer set (10pMml
 1), 10ml of METH-
2 primer set (10pMml
 1) and 32.75ml ddH2O. cDNA was amplified
under the following conditions: 951C for 5min, followed by 30
cycles of 941C for 1min, 591C for 30s, 721C for 30s and a final
extension step of 721C for 10min. Finally, 5ml of the resulting PCR
product was visualised by electrophoresis through a 3% agarose
gel containing ethidium bromide.
Homozygous deletion screening in lung cancer cell lines
To determine whether the chromosomal region containing the
METH-2 gene was deleted in lung cancer, 100ng of genomic cell
line DNA was amplified by PCR using METH-2 primers located
within exon 2 (forward: 50-TGC GTA ACT TCT GCA ACT GG-30)
and intron 2 (reverse: 50-CTT TGA TCT GCC CAT CCT GT-30).
PCR mix was composed of 1ml DNA, 5ml1 0   buffer, 0.5U of
Roche Taq polymerase, 1ml dNTPs (5mM), 1ml primers
(10pmolml
 1) and 32.75ml ddH2O. The reaction profile was 951C
for 5min, followed by 30 cycles of 941C for 1min, 581C for 30s,
721C for 30s and a final extension of 72
oC for 10min. Finally, 5ml
of PCR product was visualised by electrophoresis through a 1%
agarose gel containing ethidium bromide.
Methylation analysis
Sodium bisulphite treatment of DNA A2mg portion of genomic
DNA was digested with 20U of HindIII in a total volume of 50ml
for 6h at 371C and subsequently denatured by adding NaOH to a
concentration of 0.3 M and incubating at 421C for 20min. A
saturated sodium bisulphite solution was made by the addition of
5.4g sodium metabisulphite (Sigma S-9000) and 0.01g hydro-
quinone (Sigma H-9003) in 10ml of distilled water. pH was
brought to 5.0 with NaOH. A 950ml volume of the resulting
solution was added to the DNA samples, which were then
incubated at 551C for 16h.
DNA was recovered using Wizard
s DNA Clean-Up System
(Promega, UK) following the manufacturer’s protocol. Desulpho-
nation was achieved by the addition of NaOH to a concentration of
0.3 M and incubation at 371C for 30min. DNA was precipitated
with ammonium acetate/ethanol, recovered by centrifugation and
eluted in 50ml of 1mM Tris-HCl and 0.1mM EDTA (pH 8.0). DNA
samples were stored at  201C until use.
Competitive methylation-specific PCR We have designed a
competitive methylation-specific PCR (cMSP) assay by combining
methylation-specific primers (forward: 50-CGCGGTATAGGTT-
GATCGTC-30; reverse: 50-GTACTACGCCTAACGCCCG-30) that lie
in the CpG island located in exon 1 of METH-2 and methylation-
independent primers (forward: 5-TTGATTGGGGTTTGAGAG-
GATT-3; reverse: 50-CCCAACTAACCACACTCCAAACT-30) that
anneal in intron 3 of the gene. The PCR mix was composed of
5ml2  QIAGEN Multiplex PCR Master Mix (Qiagen, UK),
0.35pmol control primers, 5pmol methylation-specific primers
and 2ml of bisulphite-treated DNA. The reaction profile was 951C
for 15min followed by 36 cycles consisting of 941C for 30s, 601C
for 40s, 721C for 70s and a final extension of 721C for 20min. PCR
products (control: 299bp; methylation-specific: 169bp) were
analysed on agarose gels as well as chip capillary electrophoresis
(Agilent 2100 Bioanalyser).
Allelic imbalance analysis at the METH-2 locus
Allelic imbalance (AI) in METH-2 was assessed in 23 normal/
tumour pairs using an intragenic, intronic single nucleotide
polymorphism (SNP): rs1552330 (NCBI). SNP templates were
generated by PCR using the same reaction mix and reaction profile
used for homozygous deletion screening. PCR primers were as
follows: forward, 50-ATGGAGTCTTCCCAGGTGGT-30; reverse, 50-
TGCCAAAGCTGGTCTCACTA-30.A1 0ml volume of PCR template
was then digested with 5U BstUI in a total volume of 30ml for 3h
at 601C. A 20ml portion of the digested template was visualised by
electrophoresis through a 3% agarose gel containing ethidium
bromide. Allelic imbalance was visually assessed as an imbalance
of the band (digested-to-undigested) ratio in comparison to the
normal counterpart.
Immunohistochemical analysis of METH-2
Immunohistochemical (IHC) analysis was performed on 32 5mm
formalin-fixed, paraffin-embedded sections with METH-2 anti-
body (1:500 dilution) (METH-2 AB-1, Oncogene Research
Products; cat#PC508). Primary antibody was diluted in DAKO
ChemMatet antibody diluent containing blocking protein (code
no. S 2022). Each run comprised tumour lung tissue sections with
paired normal when available, a positive control tissue section
(normal human stomach or sigmoid colon – previously deter-
mined using a tissue microarray containing 35 different human
tissue types) and a negative control (no primary antibody) for each
of these sections. Tissues were first dewaxed, followed by
endogenous peroxidase blocking in 3% peroxide solution. Tissues
were then subjected to antigen retrieval by microwaving for 15min
in antigen unmasking solution (Vector Laboratories Inc., Burlin-
game, CA 94010, USA; cat#H-3300), then stained for 1h with
METH-2 primary antibody. Tissues were incubated with a
biotinylated anti-rabbit secondary antibody, followed by strepta-
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svidin incubation, then detection with DAB chromogen (DAKO
LSAB2 Peroxidase system). Protein expression was scored by two
independent pathologists (MS and ES); each section was assessed
as to the location, intensity and proportion of cells positive with
the antibody. Intensity was defined as negative, weak and strong.
RESULTS
METH-2 expression in primary NSCLC
Comparative multiplex RT–PCR (cmRT–PCR) analysis of METH-
2 in 23 paired normal and lung cancer tissue cDNAs demonstrated
a dramatic reduction of METH-2 transcript in 23 out of 23 (100%)
lung tumour samples (Figure 1). We have also undertaken IHC
analysis in 20 NSCLC tissue sections (11 ADC and nine SCC) and
11 histologically normal adjacent lung sections. METH-2 protein is
expressed in the bronchial epithelium and specifically in the
cytoplasm of the ciliated cells (Table 1, Figure 2A and B). Bronchial
epithelium in adjacent normal tissue sections presented strong
cytoplasmic staining in eight out of 11 (73%) samples, weak
staining in two samples and negative staining in one sample.
Interestingly, eight of the examined tumour sections contained
some normal respiratory mucosa incidentally present within or
adjacent to the tumour sample (listed in the ‘NT’ column of Table 1,
also see Figure 2C and D). Six out of these eight showed strong and
two weak staining. In contrast, only one out of 20 tumour section
was strongly positive, nine were weakly positive and 10 were
negative (Table 1, Figure 2C and D), which constitutes a significant
difference compared to both the adjacent normal (Fisher’s test,
P¼1.2 10
 4) and the ‘internal’ normal (Fisher’s test,
P¼3.8 10
 4) areas.
In this small series, staining for METH-2 protein did not
correlate with tumour histology, differentiation, TNM status or age
of the patient.
Methylation status of METH-2 promoter
For the methylation analysis of the promoter region of METH-2,
we included the samples used for expression analysis plus a further
set of 27 available NSCLC DNAs, leading to a total of 50 NSCLC
samples (24 ADC and 26 SCC). A total of 29 samples (58%)
demonstrated hypermethylation of the METH-2 promoter
(Figure 3). METH-2 hypermethylation was more frequent in
ADC (16 out of 24, 67%) than SCC (13 out of 26, 50%) although
this difference is not statistically significant (Fisher’s test,
P¼0.18). Methylation in normal tissue was found only in one
case (sample L352) while the rest were negative. The methylation
status of the METH-2 promoter did not correlate with age,
differentiation or TNM status.
Homozygous deletion and allelic imbalance analysis of
METH-2
No homozygous deletions of METH-2 were identified in any lung
cancer cell lines tested, with a clear PCR product amplifiable in
Table 1 METH-2 expression and methylation results in relation to clinicopathological parameters
mRNA expression Protein expression
Methylation
Hist. no. Age Histology Differentiation T status N status N T Nadj NT TN T
L124 65 AdC Poor 2 0 + k NA NA NA   +
L298 68 AdC Poor 2 2 + k Strong/C NA Reduced/B   
L308 68 AdC Poor 2 0 + k NA NA Reduced/B   +
L314 52 AdC Poor 2 2 + k Strong/B NA Reduced/B   +
L323 74 AdC Poor 2 2 + k Reduced/A Strong/B Negative   +
L326 53 AdC Moderate 2 0 + k Strong/B Reduced/C Negative   
L336 73 AdC Poor 2 1 + k Reduced/B NA Negative   
L341 58 AdC Moderate 2 0 + k Negative Strong/B Reduced/B   
L352 61 AdC Poor 2 1 + k NA Reduced/C Reduced/C + +
L353 67 AdC Poor 2 1 + k Strong/C NA Negative   +
L358 68 AdC Poor 2 2 + k NA Strong/C Reduced/B   
L378 55 AdC Poor 2 1 + k Strong/B Strong/C Negative   +
L112 74 SqCC Moderate 2 0 + k NA NA Negative   
L144 61 SqCC Moderate 2 0 + k NA NA Negative   
L151 70 SqCC Poor 2 1 + k NA NA Negative   
L152 56 SqCC Well 2 1 + k NA Strong/C Reduced/C   
L153 67 SqCC Moderate 2 0 + k NA NA Reduced/A   +
L161 76 SqCC Moderate 2 0 + k NA Strong/C Negative   +
L177 71 SqCC Moderate 2 0 + k NA NA Negative   +
L180 45 SqCC Well 2 1 + k Strong/B NA NA   
L362 52 SqCC Moderate 2 1 + k NA NA NA   
L371 60 SqCC Moderate 2 1 + k Strong/C NA Reduced/A   
L373 69 SqCC Moderate 2 0 + k Strong/B NA Strong/B   
Histology: AdC¼adenocarcinoma, SqCC¼squamous cell carcinoma. mRNA expression: +¼METH-2 transcript equally detectable with control gene, k¼reduced METH-2
transcript. Protein expression: Nadj¼adjacent normal, NT¼normal within tumour section, T¼tumour. Protein expression, staining score: A¼less than 5% of cells, B¼less than
50%, C¼greater than 50%, NA¼no available data.
124 144 151 314 308 352 362
N    T      N    T     N     T      N     T     N    T      N     T   N    T
Figure 1 Relative expression levels of METH-2 in paired normal and
tumour lung tissues. Patient numbers are shown. The heavier band
represents the control gene (O28) and the lower band represents METH-
2. A remarkable reduction of METH-2 transcript is observed in all tumour
samples. N: normal; T: tumour.
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seach case. Allelic imbalance analysis of METH-2 using an RFLP
assay for the rs1552330 intronic SNP demonstrated nine hetero-
zygous and 14 homozygous (noninformative) samples. Allelic
imbalance was observed in four out of nine (44%) of the
informative samples (Figure 4). Allelic imbalance was demon-
strated as a change in the allele ratio between normal and tumour
rather than a complete loss of one allele in tumour. Incomplete loss
of an allele is likely to be due to the presence of normal
contaminating cells in the tumour sections.
DISCUSSION
Angiogenesis is regulated through a balance of angiogenic and
antiangiogenic factors, and the angiogenic switch, which permits
the expansion of a small neoplastic lesion, is a key event in tumour
progression (Cox et al, 2000). Angiogenesis is also critically
important in the context of the growth of disseminated micro-
metastases, which may conceivably be triggered by the surgical
removal of a primary lesion (O’Reilly et al, 1999). In this study, we
have validated the expression pattern of the antiangiogenic factor
METH-2 in NSCLC following the identification of the tumour
under-representation of its transcript in a microarray analysis of
primary disease (Heighway et al, 2002). Furthermore, we have
investigated plausible genetic and epigenetic phenomena such as
allelic loss, homozygous deletions and promoter hypermethylation
that may be responsible for this downregulation.
The sequence of METH-2 was originally identified during an
attempt to find novel cDNAs with a thrombospondin type I (TSP-
1) antiangiogenic domain (Vazquez et al, 1999). METH-2 is highly
expressed in adult and fetal lung, and is found at lower levels in the
brain, placenta, heart, stomach and fetal brain and kidney.
Immunohistochemical detection of METH-2 protein in this study
demonstrated strong cytoplasmic localisation in the differentiated
bronchial epithelial cells of the majority of the normal samples.
In this study, METH-2 gene mRNA expression was dramatically
reduced relative to histologically normal epithelial cells in all
NSCLC tissues tested. Given that the tumours were randomly
selected from our database, and were independent of those
analysed in the initial microarray study, this downregulation is
likely to represent a common state for neoplastic lung tissue. This
global reduction of METH-2 transcript and protein in the lung
tumour tissues could suggest either that the gene is abnormally
downregulated in tumour providing a possible selective advantage,
or alternatively that the low level of expression seen is more typical
of the tumour progenitor cell.
Concerning the possible causes of METH-2 silencing, interest-
ingly, more than 50% of tumours demonstrated the presence of
hypermethylated alleles in the gene’s promoter region, with the
majority (49 out of 50) of normal samples showing no methylation.
These results suggest that DNA methylation may be an important
mechanism of transcriptional inactivation of METH-2 in NSCLC.
The MSP approach we used is not quantitative; therefore, no
conclusions can be currently drawn regarding the percentage of
cells carrying methylated alleles. Further investigations using a
real-time or cloning and sequencing approach are required to
clarify this issue and demonstrate the precise impact of methyla-
tion on METH-2 silencing. We have also shown in a small number
of cases using an internal SNP that allelic loss occurred in four out
of nine informative samples. The use of additional SNPs and/or
microsatellites in the region providing higher percentage of
heterozygotes is required in future studies to confirm this initial
observation.
Comparative multiplex RT–PCR analysis of METH-2 demon-
strated no discernable expression in the 23 specimens under
investigation, thus no valid associations could be made between
the presence of DNA methylation and mRNA expression.
Similarly, with only one out of 20 tumours showing strong
expression of the METH-2 protein, no association between DNA
methylation and METH-2 protein expression could be made.
Nonetheless, it appears that METH-2 silencing is universal in
NSCLC due to a number of reasons, which include DNA
methylation and AI-associated abnormalities. However, a larger
series of samples must be investigated to verify this hypothesis. We
Figure 2 Immunohistochemical detection of METH-2 protein in lung tissues. (A, B) Normal lung. Positive staining is observed in ciliated bronchial
epithelial cells (arrows). (C, D) Lung adenocarcinoma showing weakly positive tumour cells (T) and moderately positive staining of adjacent normal
bronchial epithelium (N). Counterstained with H&E. Magnification: (A, D)  10; (B, C)  20.
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shave not observed homozygous deletions of METH-2 in a panel of
lung cancer cell lines, suggesting that this phenomenon may be
infrequent in NSCLC.
The protein levels in tumours were low in 19 out of 20 samples
and this observation is consistent with the observed mRNA
transcript downregulation. It is noteworthy that although a METH-
2 transcript was diminished in all tumours by RT–PCR, nine out
of 20 tumours demonstrated reduced but not negative expression.
Also, in certain instances, normal bronchial epithelium within the
tumour sections stained positive in these samples. It is likely that
the transcript copy number in such samples was too low to be
detected under the RT–PCR conditions used. We must also
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Figure 3 (A) METH-2 cMSP analysis on lung tumour DNAs. The presence of the methylation-independent control fragment (299bp) confirms sufficient
amount of converted DNA in the reaction, while the presence of the methylation-specific product (169bp) demonstrates the existence of methylated
copies. DNAs from tumours 341, 371 and 180 show no methylation of METH-2, while those from 314, 308, 124, 177, 161 and 153 demonstrate
methylation of the METH-2 promoter. N: negative (unmethylated) control; P: positive (methylated with SssI methylase) control; M: X174/HaeIII. (B)
Capillary electrophoretic analysis of METH-2 cMSP products on Agilent Bioanalyser 2100 DNA chip. The presence of the methylation-independent control
peak (299bp) indicates sufficient amount of converted DNA, while the presence of the methylation-specific product peak (169bp) demonstrates the
existence of methylated copies.
151       353        308        341      124   
N   T      N    T     N   T     N    T     N    T
Figure 4 Allelic imbalance analysis of METH-2 using an intragenic SNP
marker. Five heterozygotes are demonstrated. Sample pairs 151, 353 and
124 show no AI. Sample pairs 341 and 308 show AI in the tumour tissue
(indicated by the disturbance of the allele ratios compared to the normal).
METH-2 hypermethylation in NSCLC
JR Dunn et al
1153
British Journal of Cancer (2004) 91(6), 1149–1154 & 2004 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sconsider the possibilities that (a) depending on the half-life in the
tumour cell, protein may be present in the absence of amplifiable
transcript, and (b) that any unmatched IHC and RT–PCR results
could be due to the topographically different section of the tissue
samples used for each procedure.
Immunohistochemical analysis revealed three normal adjacent
epithelium areas (in patients L323, L336 and L341; see Table 1)
with apparently reduced protein expression but clearly detectable
levels of mRNA. One possibility is that post-transcriptional
modification may be responsible for the apparent reduction of
observed protein levels in these cells. This is also supported by the
fact that methylation, which appears to be a significant cause of
silencing in tumours, was only observed in a single normal sample.
Three tumour samples (L352, L308 and L314) showed protein
expression and also promoter hypermethylation (see Table 1). It is
likely that METH-2 hypermethylation in these cases was partial
and not sufficient to silence the gene completely.
The downregulation of expression seen in normal epithelium
poses a question on the timing and significance of such events.
There were no data in this study to indicate more frequent or
greater loss of METH-2 expression in advanced disease. However,
all the samples examined for expression and the vast majority of
samples examined for methylation were staged as T2, minimising
the chance of statistically valid conclusions. In addition, no
metaplastic or dysplastic sites were observed in the sections
examined; thus, the status of METH-2 in lung preneoplasia still
remains to be clarified.
In conclusion, we have highlighted METH-2 as a gene that is
dramatically downregulated in NSCLC. In many cases, promoter
hypermethylation and AI appear to have an effect on this. The
striking downregulation observed in all tumours examined and the
potential of the gene product as an antiangiogenic therapeutic
agent certainly make it worthy of further investigation.
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